RecruitingPhase 4

Intra-sheath vs Extra-sheath Injection for De Quervain's Tenosynovitis

United States80 participantsStarted 2022-01-24

Plain-language summary

The aim of the study is to determine whether or not extra-sheath steroid injections are inferior to intra-sheath steroid injections in the treatment of DeQuervain's Tenosynovitis. Patients will be randomized to either the intra-sheath group or the extra-sheath group and their pre-injection level of pain will be assessed using the visual analog scale. Appropriate injections will then be administered by 1 of 3 UC Davis hand surgeons. Six weeks post injection the patients will be reassessed using the visual analog scale and their score at 6 weeks will be compared to their pre-injection score.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed informed consent from the patient exclusively and not a legal representative * Clinically diagnosed with De Quervain's * VAS score of at least 40mm pre-injection * Life expectancy greater than 1 year Exclusion Criteria: * Having previously undergone steroid injection in the treatment of De Quervain's * Having previously undergone surgery for De Quervain's in the affected wrist * Having previously undergone steroid injection and failed in the treatment of trigger finger * Allergies to lidocaine or dexamethasone * Underlying serious medical conditions that would place the patient at risk * Past history of hypothyroidism or rheumatoid arthritis * Pregnant women * Prisoners

What they're measuring

Visual analog scale (VAS) at 6 weeks post injection

Timeframe: 6 weeks

Trial details

NCT IDNCT04895956

SponsorUniversity of California, Davis

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-01

Contact for this trial

Julia Martin, MS

916-7348175 jyhmartin@ucdavis.edu